Drug intelligence / Profile preview

ciclopirox olamine

Development stage
Approved
Lead developer
Stiefel
Modality
Small Molecules
Administration
Topical
01

Overview

Ciclopirox olamine leave-on solution is a topical antifungal formulation developed by Stiefel Laboratories (a GSK company). It contains the small molecule **ciclopirox olamine**, which exerts its antifungal effect by chelating polyvalent metal cations, such as Fe3+ and Al3+, which are essential cofactors for enzymes in fungal cells. This chelation leads to the inhibition of metal-dependent enzymes like cytochromes, catalase, and peroxidase, ultimately impairing fungal nutrient uptake and cell membrane integrity. The leave-on solution is specifically designed for the treatment and prophylaxis of dandruff and seborrhoeic dermatitis, particularly those associated with the yeast *Malassezia furfur*. Unlike rinse-off shampoos, this formulation is intended to remain on the skin or scalp to provide prolonged exposure to the active ingredient. It has been evaluated in Phase 1 studies to assess skin irritation potential compared to vehicle and other marketed solutions.

Brand names
StiproxStieprox
Other names
CPOciclopirox olamine solution
02

Targets

Fe3+ (Ferric iron)

Beyond the preview

Go deeper on ciclopirox olamine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ciclopirox olamine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call